Acetyllevocarnitine Hydrochloride for the Treatment of Diabetic Peripheral Neuropathy: A Phase 3 Randomized Clinical Trial in China.

Diabetic peripheral neuropathy (DPN) is a highly prevalent chronic complication in type 2 diabetes (T2D) for which no effective treatment is available. In this multicenter, randomized, double-blind, placebo-controlled phase 3 clinical trial in China, patients with T2D with DPN received acetyllevocarnitine hydrochloride (ALC; 1,500 mg/day; n = 231) or placebo (n = 227) for 24 weeks, during which antidiabetic therapy was maintained. A significantly greater reduction in modified Toronto clinical neuropathy score (mTCNS) as the primary end point occurred in the ALC group (-6.9 ± 5.3 points) compared with the placebo group (-4.7 ± 5.2 points; P < 0.001). Effect sizes (ALC 1.31 and placebo 0.85) represented a 0.65-fold improvement in ALC treatment efficacy. The mTCNS values for pain did not differ significantly between the two groups (P = 0.066), whereas the remaining 10 components of mTCNS showed significant improvement in the ALC group compared with the placebo group (P < 0.05 for all). Overall results of electrophysiological measurements were inconclusive, with significant improvement in individual measurements limited primarily to the ulnar and median nerves. Incidence of treatment-emergent adverse events was 51.2% in the ALC group, among which urinary tract infection (5.9%) and hyperlipidemia (7.9%) were most frequent.

An efficient and thermally stable Cr3+-activated Y2GdSc2Al2GaO12 garnet phosphor for NIR spectroscopy applications.

Near-infrared (NIR) spectroscopy realized by an NIR phosphor-converted light-emitting diode (pc-LED) as a light source has aroused considerable interest due to its numerous merits and widespread application scenarios. Nevertheless, developing NIR emitting phosphors with high performance is still the top priority. Here, we report a new Y2GdSc2Al2GaO12:Cr3+ (YGSAG:Cr3+) garnet phosphor, which demonstrates a broadband emission peaking at 754 nm with a full width at half maximum (FWHM) of around 120 nm in the range of 650-1200 nm. The YGSAG:0.08Cr3+ sample irradiated by blue light exhibits the most intense emission intensity, leading to a high absorption efficiency of 49.54%. In addition, compared with room temperature, the integrated PL intensity of the sample can still be maintained at 90.97% at 423 K. Benefitting from the outstanding optical properties, the as-manufactured NIR pc-LED device driven by a 100 mA current represents a high NIR output power of 35.14 mW and a photoelectric efficiency of 12.51%. These results verify that the as-synthesized YGSAG:Cr3+ phosphor possesses great potential for the applications of NIR spectroscopy.

A randomized, double-blind, placebo controlled, phase 3 trial to evaluate the efficacy and safety of cetagliptin added to ongoing metformin therapy in patients with uncontrolled type 2 diabetes with metformin monotherapy.

AIM: This trial was designed to assess the efficacy and safety of cetagliptin added to metformin in Chinese patients with type 2 diabetes who had inadequate glycaemic control with metformin monotherapy. METHODS: In total, 446 patients with type 2 diabetes on metformin monotherapy were randomized to receive the addition of once-daily cetagliptin 100 mg, cetagliptin 50 mg and placebo in a 2:2:1 ratio for 24-week double-blind treatment. At week 24, patients initially randomized to cetagliptin 50 mg and placebo were switched to cetagliptin 100 mg for 28 weeks open-label treatment. The primary endpoint was the change in haemoglobin A1c (HbA1c) from baseline, and the efficacy analyses were based on an all-patients-treated population using an analysis of co-variance. RESULTS: After 24 weeks, both add-on therapies led to greater glycaemic control. Reductions in HbA1c from baseline were -1.17 ± 0.794%, -1.23 ± 0.896% in cetagliptin 100 mg and 50 mg plus metformin group, respectively. No difference was observed between the cetagliptin 100 mg and 50 mg plus metformin group. Patients with higher baseline HbA1c levels (≥8.5%) experienced greater reductions in HbA1c. A significantly greater proportion of patients achieved an HbA1c <7.0% with cetagliptin 100 mg (49.4%) and cetagliptin 50 mg (51.1%) plus metformin than metformin monotherapy (14.4%). Both combination therapies also improved the homeostasis model assessment ß-function index and decreased systolic blood pressure. There was no increased risk of adverse effects with combination therapy, and both combination therapies were generally well tolerated. CONCLUSIONS: The addition of cetagliptin once daily to metformin was more efficacious and well tolerated than metformin monotherapy in Chinese patients with type 2 diabetes who had inadequate glycaemic control with metformin monotherapy.

Near-Infrared LuCa2ScZrGa2GeO12:Cr3+ Garnet Phosphor with Ultra-broadband Emission for NIR LED Applications.

Near-infrared phosphor-converted light-emitting diodes (NIR pc-LEDs), as a new generation of NIR lighting sources, have wide prospects in the areas of food analysis and biological and night vision imaging. Nevertheless, NIR phosphors are still limited by short-wave and narrowband emissions as well as low efficiency. Herein, a series of NIR phosphors, LuCa2ScZrGa2GeO12:Cr3+ (LCSZGG:Cr3+), with broadband emissions have been developed and first reported. At 456 nm excitation, the optimized LCSZGG:0.005Cr3+ phosphor represents an ultra-broadband emission within the range of 650-1100 nm, peaking near 815 nm with a full width at half maximum of 166 nm. Furthermore, the LCSZGG:0.005Cr3+ phosphor possesses good internal quantum efficiency of 68.75%, and its integrated emission intensity at 423 K still retains about 64.17% of that at room temperature. By combining the optimized sample with a blue chip, a NIR pc-LED device is fabricated, which has an excellent NIR output power of 37.88 mW with an NIR photoelectric conversion efficiency of 12.44% under a 100 mA driving current. The aforementioned results demonstrate that these LCSZGG:Cr3+ broadband NIR phosphors are expected as NIR light sources.

Recent Advances in Multi-Site Luminescent Materials: Design, Identification and Regulation.

The development of novel phosphor materials with excellent performance and modification of their photoluminescence to meet the higher requirements for applications are the essential research subjects for luminescent materials. Multi-site luminescent materials with crystallographic sites for the activator ions that broaden the tunable range of luminescent spectra and even enhance the luminescent performance have attracted significant attention in the pursuit of high-quality luminescence for white light-emitting diodes. Here, we summarize multi-site luminescence characteristics based on the different kinds of host and activator ions, introduce the identifications of multi-site activator ions via optical analysis, provide a structural analysis and theoretical calculation methods, and introduce the regulation strategies and advance applications of multi-site phosphors. The review reveals the relationship between crystal structure and luminescent properties and discusses future opportunities for multi-site phosphors. This will provide guidance for the design and development of luminescent materials or other materials science.

Multisite Cation Regulation of Broadband Cyan-Emitting (Ba1-xSrx)9Lu2Si6O24/Eu2+ Phosphors for Full-Spectrum wLEDs.

Developing broadband cyan-emitting phosphors is an essential issue to achieve high-quality full-spectrum phosphor-converted white light-emitting diodes. Multisite cation regulation to modify the photoluminescence spectrum is a valid way to achieve broadband emission for phosphors. The Ba9Lu2Si6O24 lattice with various cation sites for activator ions is a preferred host for broadband emitting phosphors. The preferential crystallographic sites of Eu2+ in the Ba9Lu2Si6O24 lattice are identified based on the crystal field theory, crystal structure, and bond indices (such as NAC and SBOs) of the cations. Sr substitution in Ba9Lu2Si6O24/Eu2+ phosphor affects the location of Eu2+ activator ions, which is investigated via the first-principles density functional theory calculations, Rietveld refinement, and luminescence decay curves, and results in the modification of luminescence properties and thermal stability. The Sr-substituted (Ba0.8Sr0.2)9Lu2Si6O24/Eu2+ sample exhibits a broadband emission spectrum peaked at 471 and 518 nm with a large full width half maximum of 139 nm, covering blue-cyan-green regions, which can be an excellent candidate as broadband cyan-emitting phosphors for high-quality full-spectrum wLEDs.

Garnet phosphors for white-light-emitting diodes: modification and calculation.

Phosphor-converted white-light-emitting diodes (pc-wLEDs) have attracted considerable attention in general lighting and backlight display applications due to their high efficiency and long lifetime. The combination of Ce3+-doped yttrium aluminium garnet (YAG:Ce3+) with a blue LED chip is the most mature technology to obtain white light emission. Because of the excellent structural flexibility of garnet, many novel garnet phosphors have been designed and developed in the past few years. In this Frontier article, we describe our results related to the modification and calculation of garnet phosphors. The modification of YAG:Ce3+ phosphors is divided into five types depending on the crystallographic sites of substitution, and the effects of each on the structure and luminescence properties are illustrated in detail. Additionally, we outline our recent research progress in first-principles calculations of garnet phosphors with an emphasis on the analysis and prediction of their structure and luminescence performance. Finally, the status quo of pc-wLEDs using garnet phosphors, as well as the potential problems and future developments of garnet phosphors, are also discussed.